Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Immunotherapy for cancer sometimes has autoimmune complications, and immunotherapy for autoimmunity can compromise microbial defence and immunosurveillance. In this article, Rachel Caspi explores the potential penalties of successful immunotherapeutic approaches and highlights the need for more specific modalities.